ATE360433T1 - Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose - Google Patents

Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose

Info

Publication number
ATE360433T1
ATE360433T1 AT98950411T AT98950411T ATE360433T1 AT E360433 T1 ATE360433 T1 AT E360433T1 AT 98950411 T AT98950411 T AT 98950411T AT 98950411 T AT98950411 T AT 98950411T AT E360433 T1 ATE360433 T1 AT E360433T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
apm1
smooth muscle
methods
compositions
Prior art date
Application number
AT98950411T
Other languages
English (en)
Inventor
Yuji Matsuzawa
Yasukazu Ohmoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE360433T1 publication Critical patent/ATE360433T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
AT98950411T 1997-10-29 1998-10-27 Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose ATE360433T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29756997 1997-10-29

Publications (1)

Publication Number Publication Date
ATE360433T1 true ATE360433T1 (de) 2007-05-15

Family

ID=17848257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950411T ATE360433T1 (de) 1997-10-29 1998-10-27 Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose

Country Status (10)

Country Link
US (3) US6461821B1 (de)
EP (1) EP1033134B8 (de)
JP (2) JP3538711B2 (de)
AT (1) ATE360433T1 (de)
CY (1) CY1106616T1 (de)
DE (2) DE69837678T2 (de)
DK (1) DK1033134T3 (de)
ES (1) ES2285786T3 (de)
PT (1) PT1033134E (de)
WO (1) WO1999021577A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO2000026363A1 (en) 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
ES2323445T3 (es) 1999-02-10 2009-07-16 Serono Genetics Institute S.A. Marcadores polimorficos del gen lsr.
CN1341027A (zh) 1999-02-19 2002-03-20 津莫吉尼蒂克斯公司 止血和免疫功能的抑制剂
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
JP4689787B2 (ja) * 1999-04-12 2011-05-25 住友化学株式会社 腹腔内脂肪組織量の分析方法
WO2001032868A1 (en) * 1999-11-04 2001-05-10 Genset Apm1 biallelic markers and uses thereof
ATE405655T1 (de) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
ATE464378T1 (de) * 2000-05-31 2010-04-15 Serono Genetics Inst Sa Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
US20020132773A1 (en) * 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
WO2003011325A1 (en) * 2001-07-27 2003-02-13 Genset S.A. Agonists and antagonists of moceptin for the treatment of metabolic disorders
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
EP1414483A1 (de) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonisten und antagonisten von moxifin zur behandlung von stoffwechselerkrankungen
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
EP1418935A1 (de) * 2001-08-01 2004-05-19 Genset S.A. Genobix agonisten und antagonisten zur verwendung bei der behandlung von stoffwechselkrankheiten
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
US7276342B2 (en) 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003011320A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of obesingen for the treatment of metabolic disorders
WO2003013580A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Tr xidatin agonists and antagonists treatment of metabolic disorders
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
WO2003013579A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Lypergix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013582A1 (en) * 2001-08-06 2003-02-20 Genset S.A. Genoxit agonists and antagonists for use in the treatment of metabolic disorders
AU2002328173A1 (en) * 2001-08-07 2003-02-24 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013604A2 (en) * 2001-08-09 2003-02-20 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
DK1426764T3 (da) 2001-08-17 2011-06-27 Fujirebio Kk Fremgangsmåde til diagnosticering eller monitorering af fejl i sukkermetabolisme
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
WO2003041738A1 (en) * 2001-11-15 2003-05-22 Genset S.A. Treatment of metabolic disorders with xitar agonists and antagonists
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
WO2003045421A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Agonists and antagonists of ryzn for the treatment of metabolic disorders
US7344843B2 (en) 2001-11-29 2008-03-18 Serono Genetics Institute S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
WO2003047615A1 (en) * 2001-12-05 2003-06-12 Genset S.A. Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002339683A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Agonist and antagonists of redax for the treatment of metabolic disorders
WO2003049757A1 (en) * 2001-12-12 2003-06-19 Genset S.A. Agonists and antagonists of glucomin for the treatment of metabolic disorders
WO2003049756A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Glucomin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339685A1 (en) * 2001-12-13 2003-06-23 Genset S.A. Agonists and antagonists of oxifan for the treatment of metabolic disorders
WO2003049758A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) * 2001-12-14 2003-06-30 Genset S.A. Glucoset agonists and antagonists for use in the treatment of metabolic disorders
WO2003055509A1 (en) * 2001-12-26 2003-07-10 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
WO2003062275A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
DE60329000D1 (de) * 2002-05-24 2009-10-08 Japan Science & Tech Agency C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose
JP4509933B2 (ja) * 2003-03-24 2010-07-21 三菱化学メディエンス株式会社 アディポネクチン分析用ラテックス試薬及びアディポネクチン分析方法
GB0312122D0 (en) * 2003-05-27 2003-07-02 Pharmagene Lab Ltd Therapeutic method
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
DE102004042530B4 (de) * 2004-09-02 2006-10-19 Mosaiques Diagnostics And Therapeutics Ag Verfahren zur Diagnose von Arteriosklerose
WO2006062422A1 (en) * 2004-12-10 2006-06-15 Protemix Corporation Limited Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions
US7678886B2 (en) * 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
EP1833845A2 (de) * 2005-01-07 2007-09-19 Xencor Adiponectinvarianten
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7592423B2 (en) * 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US20070054359A1 (en) * 2005-07-11 2007-03-08 Jonathan Zalevsky Rational Chemical Modification of Adiponectin Variants
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
EP3536336A1 (de) 2007-11-30 2019-09-11 Siemens Healthcare Diagnostics Inc. Adiponectin-rezeptor-agonisten und verfahren zur verwendung
US8268604B2 (en) * 2007-12-20 2012-09-18 Abbott Point Of Care Inc. Compositions for forming immobilized biological layers for sensing
US8241697B2 (en) 2007-12-20 2012-08-14 Abbott Point Of Care Inc. Formation of immobilized biological layers for sensing
EP2088156A1 (de) * 2008-02-08 2009-08-12 Institut Pasteur Verwendung von Adiponektin zur Diagnose und/oder Behandlung von Presbyakusis
TW201500053A (zh) * 2008-08-27 2015-01-01 Otsuka Pharma Co Ltd 用於治療肺部疾病之藥劑（二）
JP5882196B2 (ja) 2009-04-23 2016-03-09 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． アディポネクチン受容体フラグメントの単量体及び二量体形態ならびに使用の方法
KR20120104517A (ko) * 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
KR101868620B1 (ko) 2015-08-12 2018-07-23 중앙대학교 산학협력단 Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
JP4253815B2 (ja) * 1997-10-29 2009-04-15 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症予防及び治療組成物及び血管再建術後の再狭窄予防及び治療組成物

Also Published As

Publication number Publication date
WO1999021577A1 (fr) 1999-05-06
US20050163779A1 (en) 2005-07-28
DE98950411T1 (de) 2005-10-20
JP3538711B2 (ja) 2004-06-14
JP2009079064A (ja) 2009-04-16
ES2285786T3 (es) 2007-11-16
CY1106616T1 (el) 2012-01-25
EP1033134A4 (de) 2004-10-13
US7285275B2 (en) 2007-10-23
DE69837678D1 (de) 2007-06-06
US20030166551A1 (en) 2003-09-04
PT1033134E (pt) 2007-07-11
EP1033134B8 (de) 2007-09-19
DE69837678T2 (de) 2007-12-27
EP1033134A1 (de) 2000-09-06
DK1033134T3 (da) 2007-07-16
EP1033134B1 (de) 2007-04-25
US6461821B1 (en) 2002-10-08
JP4859904B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE360433T1 (de) Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose
Poggio et al. Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis
Isenberg et al. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE402188T1 (de) Bindungsproteine als biosensoren
DE69824004D1 (de) Verfahren zur quantitativen bestimmung der genexpression mit hilfe der multiplexen competitiven reversen-transkriptase polymerase kettenreaktion
ATE363074T1 (de) Substrate und screeningverfahren für transportproteine
DE60129674D1 (de) Verfahren zur diagnose von transmissiblen spongiformen encephalopathien
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
Herrmann et al. Bone marrow niches for skeletal progenitor cells and their inhabitants in health and disease
ATE500342T1 (de) Verfahren zur bestimmung von enzym aktivität
DE60034480D1 (de) Diagnostischer assay für schlaganfall
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DK0862622T3 (da) Fremgangsmåde til identifikation af forbindelser, der vekselvirker med RAC-proteinkinase
ATE384952T1 (de) Enzymhemmungsimmunverfahren
HUP0400697A2 (hu) Elcsendesített anti-CD28 ellenanyagok és használatuk
DE69115917D1 (de) Humane gammainterferonantagonisten
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest
BR0010191A (pt) Determinação de estruturas de fosfolipìdio/lipìdio complexas com auxìlio de acilglicerìdeos marcados com fluorescência sintéticos
HUP0100948A2 (hu) Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai
WO1999064861A3 (en) Method of identifying antidepressant compounds
WO2002046769A3 (en) A monoclonal antibody-based diagnostic assay for gamma fibrinogen
Kohen Mechanisms of uptake and secretion of apolipoprotein B containing triacylglycerol-rich lipoprotein in a liver cell model.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033134

Country of ref document: EP